Immune Checkpoint Inhibitor Islet Function Impairment Risk: Meta-Analysis of 31 RCTs

A 2024 meta-analysis of 31 randomized controlled trials with 15,417 cancer patients assessed the risk of islet function impairment from immune checkpoint inhibitors. The study, authored by Qi Hu and published on figshare, pooled risk ratios for hyperglycemia, diabetes mellitus, and diabetic ketoacidosis. Results indicate a significantly increased risk of severe events and type 1 diabetes associated with PD-1 inhibitors and pembrolizumab.

Use Cases

• Quantify the risk of hyperglycemia and diabetes based on pooled risk ratios from 31 RCTs.
• Compare adverse event profiles between PD-1 inhibitors and CTLA-4 inhibitors based on subgroup analyses.
• Assess the differential risk of islet function impairment in NSCLC patients versus other cancer types.
• Evaluate the safety profile of immune checkpoint inhibitor monotherapy versus combination with chemotherapy.

Strengths

• Analysis is based on 31 randomized controlled trials, a robust study design.
• Includes data from 15,417 patients, providing a substantial sample size.
• Reports specific risk ratios and confidence intervals for multiple outcomes and subgroups.
• Follows a registered protocol (PROSPERO CRD42025639629) and assesses publication bias.

Limitations

• Dataset is a 16.0 KB DOCX file; the underlying tabular data is not directly machine-readable.
• Column-level documentation is absent; field semantics must be inferred after download.
• Row count for the summary statistics table is unknown, which may limit suitability assessment.

Provenance

Source

Systematic review and meta-analysis by author Qi Hu, published on figshare.

Collection Method

Data extracted from PubMed, Embase, Cochrane, CNKI, Wanfang, CBM, and VIP databases up to October 24, 2024.

Time Range

Studies from database inception to October 24, 2024.

Freshness

Last updated 2026-03-19 06:49:58.